Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

New data from ENDORSE show positive results continued over five years with TECFIDERA® (dimethyl fumarate) in a wide range of multiple sclerosis patients
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Prevalence of neurological disorders in Al Quseir, Egypt: methodological aspects.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ...
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
Refining diagnosis of multiple sclerosis with revised MRI criteria.
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.
Architecture of human mTOR complex 1.
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA).
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Novantrone (mitoxantrone HCl) Injection February 2009
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Santhera's Phase III program with Catena®/Raxone® in Duchenne muscular dystrophy on track to deliver pivotal data early in 2Q 2014
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
Adaptive myelination from fish to man.
Immune competence after alemtuzumab treatment of multiple sclerosis.
Breastfeeding and multiple sclerosis.
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
One can prevent post-partum MS relapses by exclusive breast feeding: no.
RTL therapy for multiple sclerosis: a Phase I clinical study.

Pages